Duchenne Muscular Dystrophy Approval Race: BioMarin Pulls Back Into Lead
This article was originally published in The Pink Sheet Daily
FDA advisory committee reviews for BioMarin’s drisapersen and Sarepta’s eteplirsen, once eyed as back-to-back meetings, are now set months apart. Draft guidance may help firms overcome previous findings of inadequate data.
Register for our free email digests: